MedTrace Logo

Evaluation and Optimization of PB127 Myocardial Perfusion Echocardiography on Ultrasound Systems

NCT00487903 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2008-07-03

No results posted yet for this study

Summary

The purpose of this clinical trial is to evaluate various commercially available ultrasound systems and to identify imaging parameters to be used with these systems (along with the contrast agent PB127) as well as to further evaluate the safety of PB127.

Conditions

Interventions

DRUG

PB127 for Injectable Suspension

0.062 mg/kg continuous IV (100-250 mL/hr) during echocardiogram, single dose, infusion not to exceed 60 minutes.

Sponsors & Collaborators

  • Point Biomedical

    lead INDUSTRY

Principal Investigators

  • Alexander Ehlgen, MD, PhD · POINT Biomedical Corp.

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2008-03-31
Completion
2008-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00487903 on ClinicalTrials.gov